AU662480B2 - Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase - Google Patents

Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase

Info

Publication number
AU662480B2
AU662480B2 AU77568/91A AU7756891A AU662480B2 AU 662480 B2 AU662480 B2 AU 662480B2 AU 77568/91 A AU77568/91 A AU 77568/91A AU 7756891 A AU7756891 A AU 7756891A AU 662480 B2 AU662480 B2 AU 662480B2
Authority
AU
Australia
Prior art keywords
disorder
patient
cell proliferation
pharmaceutically acceptable
patient suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU77568/91A
Other languages
English (en)
Other versions
AU7756891A (en
Inventor
Aviv Gazit
Chaim Gilon
Alexander Levitzki
Paul E Persons
Alfred P. Spada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Rhone Poulenc Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer International Holdings Inc filed Critical Rhone Poulenc Rorer International Holdings Inc
Publication of AU7756891A publication Critical patent/AU7756891A/en
Assigned to YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM reassignment YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM Alteration of Name(s) in Register under S187 Assignors: RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.
Application granted granted Critical
Publication of AU662480B2 publication Critical patent/AU662480B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU77568/91A 1990-04-16 1991-04-16 Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase Ceased AU662480B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50998190A 1990-04-16 1990-04-16
US509981 1990-04-16
PCT/US1991/002597 WO1991016305A1 (fr) 1990-04-16 1991-04-16 Composes d'ethenediyle heterocyclique qui inhibent la kinase de tyrosine de recepteur egf

Publications (2)

Publication Number Publication Date
AU7756891A AU7756891A (en) 1991-11-11
AU662480B2 true AU662480B2 (en) 1995-09-07

Family

ID=24028875

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77568/91A Ceased AU662480B2 (en) 1990-04-16 1991-04-16 Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase

Country Status (6)

Country Link
EP (1) EP0527181A4 (fr)
JP (1) JPH05507072A (fr)
AU (1) AU662480B2 (fr)
CA (1) CA2080582A1 (fr)
IL (1) IL97873A0 (fr)
WO (1) WO1991016305A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
DE69427283T2 (de) * 1993-11-17 2001-09-13 Kyowa Hakko Kogyo Kk Propenon-derivate
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
WO1996035665A1 (fr) * 1995-05-10 1996-11-14 Kyowa Hakko Kogyo Co., Ltd. Derives de propenone
US6444694B1 (en) * 1995-06-06 2002-09-03 Wyeth Styryl benzimidazole derivatives
US5710164A (en) * 1995-06-06 1998-01-20 American Home Products Corporation Diheterocyclic styryl nitriles
WO1997008934A2 (fr) * 1995-06-19 1997-03-13 Ontogen Corporation Derives d'acide aryl-acrylique convenant comme inhibiteurs de proteine-tyrosine-phosphatase
ATE259353T1 (de) * 1995-12-01 2004-02-15 Kyowa Hakko Kogyo Kk Propenonderivate
KR101170655B1 (ko) 2003-12-11 2012-08-03 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 세포 증식 질환 치료용 화합물
RU2456265C2 (ru) 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
WO2010005807A2 (fr) 2008-07-08 2010-01-14 Board Of Regents, The University Of Texas System Nouveaux inhibiteurs de la prolifération et d'activation du transducteur de signaux et activateur de la transcription (stats)
CN109414417A (zh) * 2016-03-17 2019-03-01 约翰·霍普金斯大学 通过paris的法尼基化预防或治疗帕金森症的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658567B2 (en) * 1990-04-16 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Styryl-substituted indole and pyridyl compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605382A (nl) * 1975-06-04 1976-12-07 Sumitomo Chemical Co Werkwijze voor het bereiden van indoolderivaten.
AU632992B2 (en) * 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658567B2 (en) * 1990-04-16 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Styryl-substituted indole and pyridyl compounds

Also Published As

Publication number Publication date
EP0527181A1 (fr) 1993-02-17
JPH05507072A (ja) 1993-10-14
IL97873A0 (en) 1992-06-21
EP0527181A4 (en) 1993-04-07
WO1991016305A1 (fr) 1991-10-31
CA2080582A1 (fr) 1991-10-17
AU7756891A (en) 1991-11-11

Similar Documents

Publication Publication Date Title
US5196446A (en) Certain indole compounds which inhibit EGF receptor tyrosine kinase
AU658567B2 (en) Styryl-substituted indole and pyridyl compounds
EP0580598B1 (fr) Composes heteroaryles substitues par styryle et inhibant la tyrosine-kinase du recepteur d'egf
US5656655A (en) Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
US5217999A (en) Styryl compounds which inhibit EGF receptor protein tyrosine kinase
WO1991016892A1 (fr) Composes de styryle inhibant la proteine tyrosine kinase de recepteur de facteur de croissance epidermique
US5710158A (en) Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en) Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
EP0584222B1 (fr) Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
USRE37650E1 (en) Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
Traxler et al. [(Alkylamino) methyl] acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase
JPH11507355A (ja) タンパク質チロシンキナーゼｈｅｒ−２の自己リン酸化能を選択的に阻害するアリール及びヘテロアリールキナゾリン化合物
AU662480B2 (en) Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase
JP2002516851A (ja) サイクリン依存性キナーゼを阻害する医薬製造のためのインジゴイドビスインドール誘導体の使用
JPH10509708A (ja) プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
US5418245A (en) Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyrosine kinase
FI100530B (fi) Menetelmä substituoitujen diaminoftaali-imidien ja niiden analogien va lmistamiseksi
US5476851A (en) Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
MXPA97001820A (en) Compounds of pirazolo [3,4-g] quinoxaline queinhiben protein tyrosine kinase receptor dep
NZ204369A (en) Piperazine derivatives,their production,and pharmaceutical compositions which contain them
US4447607A (en) Dibenzo diazacines
IL99762A (en) Alpha-cyano-styryl-substituted pyridyl compounds which inhibit egf receptor tyrosine kinase and pharmaceutical compositions containing them
IE853326L (en) Allylic amines
WO2005113561A1 (fr) Cyclicsulfonate pyrrole indolinones en tant qu'inhibiteurs de kinase